Companies Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals (ATNM): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Actinium Pharmaceuticals, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,705,000FY2023
- $1,173,200FY2024
- $1,187,320FY2025
CEO total pay was $1,187,320 in fiscal 2025, up from $1,173,200 in fiscal 2024.
FY2025: salary $762,320 · bonus $425,000 · stock awards $0 · option awards $0
Order ATNM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sandesh Seth | $762,320 | $425,000 | $0 | $0 | $0 | $0 | $0 | $1,187,320 |
| Chairman and Chief Executive Officer | ||||||||
| Steve O’Loughlin | 445,536 | 100,901 | 0 | 0 | 0 | 0 | 0 | 546,437 |
| Former Chief Financial Officer (through February 2026) | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sandesh Seth | $1,187,320 | $1,173,200 | $4,705,000 | ↑ +14,120 |
| Steve O’Loughlin | 546,437 | 581,800 | 1,490,000 | ↓ −35,363 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
a base salary, which will be determined by the Board and adjusted to be competitively aligned to a range between the 25 th and 75 th percentile of the relevant market data of chief executive officer positions of similarly situated publicly companies
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | StreeterWyatt Analytics LLC |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
No outstanding equity awards are on file for this fiscal year.
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ajit S. ShettyIndependent · Nominating and Corporate Governance (Chair) · Audit · Compensation | $72,500 | $0 | $0 | — | $0 | $72,500 |
| David NicholsonIndependent · Lead Independent Director · Compensation (Chair) | 70,000 | 0 | 0 | — | 0 | 70,000 |
| Richard I. SteinhartIndependent · Audit (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 0 | — | 0 | 70,000 |
| Jeffrey W. ChellIndependent · Audit · Compensation | 62,500 | 0 | 0 | — | 0 | 62,500 |
| June S. AlmenoffIndependent · Nominating and Corporate Governance | 50,000 | 0 | 0 | — | 0 | 50,000 |
| Sandesh SethEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $325,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $325,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Actinium Pharmaceuticals as a peer
Companies that benchmark against ATNM
5 companies name ATNM as a compensation peer
- Atara Biotherapeutics, Inc.ATRAFY2024
- KYNTRA BIO, INC.FGENFY2025
- Passage BIO, Inc.PASGFY2025
- SELLAS Life Sciences Group, Inc.SLSFY2025
- Verastem, Inc.VSTMFY2025
Each company listed discloses ATNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Actinium Pharmaceuticals, Inc. | 2025 | Sandesh Seth | $762,320 | $0 | $0 | $0 | $1,187,320 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-10-15 | 4,481,875 | 1,541,460 | 243,885 | 74.41% | Passed |
| 2022 | 2022-12-30 | 9,832,125 | 2,559,430 | 387,341 | 79.35% | Passed |
| 2018 | 2018-12-18 | — | — | — | — | — |
| 2017 | 2017-12-20 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-10-15 | 74.41%a |
| 2022 | 2022-12-30 | 79.35%b |
| 2018 | 2018-12-18 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sandesh Seth. DEF 14A, filed 2026-10-16. Section “Executive Compensation”. As printed: 1,187,320. View filing ↗
- Section 01, Steve O’Loughlin. DEF 14A, filed 2026-10-16. Section “Executive Compensation”. As printed: 546,437. View filing ↗
- Section 08, Ajit S. Shetty. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 72,500. View filing ↗
- Section 08, David Nicholson. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 70,000. View filing ↗
- Section 08, Richard I. Steinhart. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 70,000. View filing ↗
- Section 08, Jeffrey W. Chell. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 62,500. View filing ↗
- Section 08, June S. Almenoff. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 50,000. View filing ↗
- Section 08, Sandesh Seth. DEF 14A, filed 2026-10-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-11-26. Item 5.07 · say-on-pay result. As reported: 74.41% (votes for as printed: 4,481,875). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-12-30. Item 5.07 · say-on-pay result. As reported: 79.35% (votes for as printed: 9,832,125). View filing ↗
- Section 06, 2018 vote. Form 8-K, filed 2018-12-21. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 325,000 + equity 0 + all other 0 = 325,000, summed across the director compensation table rows.
- Actinium Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗